CY1125052T1 - Κρυσταλλικες μορφες - Google Patents
Κρυσταλλικες μορφεςInfo
- Publication number
- CY1125052T1 CY1125052T1 CY20221100195T CY221100195T CY1125052T1 CY 1125052 T1 CY1125052 T1 CY 1125052T1 CY 20221100195 T CY20221100195 T CY 20221100195T CY 221100195 T CY221100195 T CY 221100195T CY 1125052 T1 CY1125052 T1 CY 1125052T1
- Authority
- CY
- Cyprus
- Prior art keywords
- crystal forms
- pharmaceutical compositions
- crystalline forms
- crystalline
- phosphono
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- -1 butyl hydrochloride Chemical compound 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Η εφεύρεση αναφέρεται σε μια κρυσταλλική μορφή της ένωσης υδροχλωρικός βουτυλεστέρας του 4-((R)-2-{[6-((S)-3-μεθοξυ-πυρρολιδιν-1-υλ)-2-φαινυλο-πυριμιδινο-4-καρβονυλο]-αμινο}-3-φωσφονο-προπιονυλο)-πιπεραζινο-1-καρβοξυλικού οξέος, μεθόδους για την παρασκευή της, φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω κρυσταλλικές μορφές, φαρμακευτικές συνθέσεις που παρασκευάζονται από τέτοιες κρυσταλλικές μορφές και τη χρήση τους ως φάρμακο, ειδικά ως ένας ανταγωνιστής του υποδοχέα Ρ2Υ12.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2016072562 | 2016-09-22 | ||
PCT/EP2017/073858 WO2018055016A1 (en) | 2016-09-22 | 2017-09-21 | Crystalline forms |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1125052T1 true CY1125052T1 (el) | 2024-02-16 |
Family
ID=59923448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100195T CY1125052T1 (el) | 2016-09-22 | 2022-03-09 | Κρυσταλλικες μορφες |
Country Status (28)
Country | Link |
---|---|
US (3) | US10730896B2 (el) |
EP (2) | EP3981774A1 (el) |
JP (1) | JP7097369B2 (el) |
KR (1) | KR102552795B1 (el) |
CN (1) | CN109715639B (el) |
AU (1) | AU2017331930B2 (el) |
BR (1) | BR112019004845A2 (el) |
CA (1) | CA3037794A1 (el) |
CL (1) | CL2019000728A1 (el) |
CY (1) | CY1125052T1 (el) |
DK (1) | DK3515924T3 (el) |
EA (1) | EA201990723A1 (el) |
ES (1) | ES2908572T3 (el) |
HR (1) | HRP20220234T1 (el) |
HU (1) | HUE057772T2 (el) |
IL (1) | IL265445B2 (el) |
LT (1) | LT3515924T (el) |
MA (1) | MA46266B1 (el) |
MX (1) | MX2019003093A (el) |
MY (1) | MY193080A (el) |
PH (1) | PH12019500567A1 (el) |
PL (1) | PL3515924T3 (el) |
PT (1) | PT3515924T (el) |
RS (1) | RS62946B1 (el) |
SI (1) | SI3515924T1 (el) |
TW (1) | TWI752086B (el) |
UA (1) | UA124073C2 (el) |
WO (1) | WO2018055016A1 (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020510043A (ja) | 2017-03-15 | 2020-04-02 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | P2y12受容体アンタゴニストの皮下投与 |
CN115803012A (zh) | 2020-07-15 | 2023-03-14 | 爱杜西亚药品有限公司 | 包含p2y12受体拮抗剂的水性医药组合物 |
MX2024000653A (es) | 2021-07-13 | 2024-01-31 | Idorsia Pharmaceuticals Ltd | Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico. |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
MXPA05006302A (es) | 2002-12-11 | 2005-08-29 | Schering Ag | Compuestos de 2-aminocarbonilquinolina como antagonistas de receptor de difosfato de adenosina plaquetario. |
CA2521313A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
AR057836A1 (es) | 2005-10-21 | 2007-12-19 | Actelion Pharmaceuticals Ltd | Piperizinas como agentes contra la malaria |
CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
BRPI0810462A2 (pt) | 2007-04-23 | 2014-10-14 | Sanofi Aventis | Derivados de quinolina-carboxamida como antagonistas de p2y12 |
US8518912B2 (en) * | 2007-11-29 | 2013-08-27 | Actelion Pharmaceuticals Ltd. | Phosphonic acid derivates and their use as P2Y12 receptor antagonists |
JP5560202B2 (ja) | 2007-12-26 | 2014-07-23 | サノフイ | P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体 |
EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
BRPI1014039A2 (pt) | 2009-04-08 | 2018-04-03 | Actelion Pharmaceuticals Ltd | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas |
US8664203B2 (en) | 2009-04-22 | 2014-03-04 | Actelion Pharmaceuticals Ltd. | Thiazole derivatives and their use as P2Y12 receptor antagonists |
JP2020510043A (ja) | 2017-03-15 | 2020-04-02 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | P2y12受容体アンタゴニストの皮下投与 |
-
2017
- 2017-09-21 KR KR1020197011330A patent/KR102552795B1/ko active IP Right Grant
- 2017-09-21 IL IL265445A patent/IL265445B2/en unknown
- 2017-09-21 AU AU2017331930A patent/AU2017331930B2/en active Active
- 2017-09-21 CA CA3037794A patent/CA3037794A1/en active Pending
- 2017-09-21 JP JP2019536696A patent/JP7097369B2/ja active Active
- 2017-09-21 PL PL17771436T patent/PL3515924T3/pl unknown
- 2017-09-21 EA EA201990723A patent/EA201990723A1/ru unknown
- 2017-09-21 HR HRP20220234TT patent/HRP20220234T1/hr unknown
- 2017-09-21 CN CN201780057793.2A patent/CN109715639B/zh active Active
- 2017-09-21 MA MA46266A patent/MA46266B1/fr unknown
- 2017-09-21 ES ES17771436T patent/ES2908572T3/es active Active
- 2017-09-21 MX MX2019003093A patent/MX2019003093A/es unknown
- 2017-09-21 RS RS20220163A patent/RS62946B1/sr unknown
- 2017-09-21 MY MYPI2019001474A patent/MY193080A/en unknown
- 2017-09-21 WO PCT/EP2017/073858 patent/WO2018055016A1/en unknown
- 2017-09-21 EP EP21206477.8A patent/EP3981774A1/en not_active Withdrawn
- 2017-09-21 TW TW106132387A patent/TWI752086B/zh active
- 2017-09-21 PT PT177714367T patent/PT3515924T/pt unknown
- 2017-09-21 SI SI201731102T patent/SI3515924T1/sl unknown
- 2017-09-21 DK DK17771436.7T patent/DK3515924T3/da active
- 2017-09-21 LT LTEPPCT/EP2017/073858T patent/LT3515924T/lt unknown
- 2017-09-21 US US16/335,973 patent/US10730896B2/en active Active
- 2017-09-21 BR BR112019004845A patent/BR112019004845A2/pt unknown
- 2017-09-21 EP EP17771436.7A patent/EP3515924B1/en active Active
- 2017-09-21 HU HUE17771436A patent/HUE057772T2/hu unknown
- 2017-09-21 UA UAA201903751A patent/UA124073C2/uk unknown
-
2019
- 2019-03-15 PH PH12019500567A patent/PH12019500567A1/en unknown
- 2019-03-21 CL CL2019000728A patent/CL2019000728A1/es unknown
-
2020
- 2020-07-24 US US16/938,730 patent/US11365209B2/en active Active
-
2022
- 2022-03-09 CY CY20221100195T patent/CY1125052T1/el unknown
- 2022-05-10 US US17/741,427 patent/US20220275011A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
CY1124855T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
CY1124848T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291 | |
CY1125052T1 (el) | Κρυσταλλικες μορφες | |
EA201990565A1 (ru) | Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
CY1123479T1 (el) | Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1 | |
EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
EA201890123A1 (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
EA201790337A1 (ru) | Кристаллические формы ингибиторов глутаминазы | |
EA201591301A1 (ru) | Новые пиримидиновые и пиридиновые соединения и их применение | |
CY1122196T1 (el) | Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων | |
CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
CY1121596T1 (el) | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα | |
EA201692356A1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
EA201790275A1 (ru) | Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида |